Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
PR Newswire
BOSTON, Aug. 6, 2026
Financial release and supplemental presentation accessible online
BOSTON, Aug. 6, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2027, which ended June 27, 2026, are available on the Company's Investor Relations website at www.haemonetics.com.
The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 6, 2026.
Conference Call and Webcast Information:
- Registration: Click here to register. Upon registration, participants will receive dial-in details and a personalized PIN. While not required, joining 10 minutes prior to the event start time is recommended.
- Live webcast: Access here or through the Investor Relations section of the Haemonetics website.
A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on August 6, 2026 and will remain accessible for one year via the webcast link above.
Earnings Materials:
Haemonetics has also posted the following materials on its Investor Relations website, which will be referenced during the conference call and webcast:
- First Quarter Fiscal 2027 Earnings Release
- First Quarter Fiscal 2027 Supplemental Earnings Presentation
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts:
Olga Guyette, Vice President-Investor Relations & Treasury
(781) 356-9763
olga.guyette@haemonetics.com
David Trenk, Sr. Manager-Investor Relations
(203) 733-4987
david.trenk@haemonetics.com
Media Contact:
Josh Gitelson, Sr. Director-Global Communications
(781) 356-9776
josh.gitelson@haemonetics.com
SOURCE Haemonetics Corporation
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States